We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Do β-Blockers Slow Down Melanoma Progression?—Reply

Vincenzo De Giorgi, MD; Marta Grazzini, MD; Sara Gandini, PhD; Silvia Benemei, MD; Niccolò Marchionni, MD; Pierangelo Geppetti, MD
Arch Intern Med. 2011;171(18):1686-1687. doi:10.1001/archinternmed.2011.484.
Text Size: A A A
Published online


In reply

Dr Lens's comment to our study, while underlining the hope for a new therapeutic option, fosters various hypotheses regarding the possible mechanisms of action of β-blockers to slow down the progression of melanoma and possibly other malignant diseases. The unprecedented ability of propranolol to treat infantile hemangiomas dictated the underlying hypothesis that led us to investigate the effect of β-blockers in patients with cutaneous malignant melanoma. The role of β-adrenoceptors to promote angiogenesis, supported by both basic and clinical evidence, represents the most robust working hypothesis explaining the beneficial effect of β-blockers in melanoma. The ability of β-adrenoceptors to enhance the VEGF pathway contributes to the identification of this mechanism as a primary target of β-blockers. The unique ability of propranolol to treat the disease and reduce VEGF levels in a child with diffuse lymphangiomatosis associated with chylothorax1 further strengthens this hypothesis. However, as appropriately underlined by Dr Lens, inhibition of additional pathways, such as the 2 metalloproteinases MMP-2 and MMP-9, which are markedly involved in angiogenesis, has also been shown for β-blockers. In addition, the proapoptotic action of β-blockers and the increased expression of the cytokines IL-6 and IL-8 by β-adrenoceptor stimulation should not be overlooked. If doubts exist regarding the mechanism responsible for the anticancer action of β-blockers, there is further uncertainty regarding the β-adrenoceptor subtype involved in cancer progression. A recent article reported that only the unselective β12-antagonist propranolol, but not the selective β1 antagonist atenolol, had a protective effect in breast cancer.2 However, an article concurrently published in the same journal issue reported that patients who showed a reduced risk of relapse with triple-negative breast cancer (as in our patients with melanoma) mostly used selective β1-receptor antagonists.3 Thus, the underlying mechanism and the specific β-adrenergic receptor subtype(s) responsible for the anticancer activity of β-blockers remain unsettled issues in both breast cancer and melanoma. Finally, it should not be disregarded that the association between β-blocker use and cancer protection has not been unanimously recognized.4 Only randomized trials can answer the question whether β-blockers may offer a novel strategy to fight cancer, and the selection of the type of cancer and the right β-blocker is a matter of current, intense debate.



Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





October 10, 2011
Marko Lens, MD, PhD, FRCS
Arch Intern Med. 2011;171(18):1686-1687. doi:10.1001/archinternmed.2011.483.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

2 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Melanoma